STOCK TITAN
  1. Home
  2. Sec-filings
  3. CAMP
  4. [Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity

CAMP Insider Filing: Director Granted 9,000 Options at $1.56 Strike

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Camp4 Therapeutics Corp. (CAMP) – Form 4 insider filing

On 06/25/2025, director Richard A. Young received a grant of 9,000 stock options with an exercise price of $1.56 per share. The award was recorded with transaction code “A,” indicating a new acquisition rather than an exercise or sale. All options vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the company’s next annual meeting of stockholders, subject to Mr. Young’s continued board service. The options expire on 06/24/2035.

Following the grant, Mr. Young beneficially owns 9,000 derivative securities linked to CAMP common stock, held directly. No open-market purchases or sales of common shares were reported, and no price was paid for the option grant itself.

Key takeaways for investors

  • Routine director compensation: single option grant, modest in size.
  • No indication of insider buying or selling of existing shares.
  • Grant terms align with standard governance practices (10-year life, one-year vesting).

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine director option grant; neutral governance impact.

The Form 4 reveals a standard equity incentive—9,000 options at a $1.56 strike—awarded to independent director Richard A. Young. Vesting and expiration terms mirror common small-cap governance practice (one-year vesting, 10-year term). No red flags such as accelerated vesting, discounted strike, or excessive size relative to peer benchmarks are present. From a governance standpoint, the filing is procedurally normal and does not materially shift insider ownership dynamics or control.

TL;DR: Neutral signal; no cash outlay, no share sale.

The transaction is an equity incentive rather than a market purchase; therefore it offers limited insight into management’s near-term outlook on CAMP stock. Size—9,000 options—is immaterial to float and market cap. Because no common shares changed hands and no premium was paid, I view the news as non-actionable for portfolio positioning.

Insider Young Richard A
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 9,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 9,000 shares (Direct)
Footnotes (1)
  1. F1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.

FAQ

What did CAMP director Richard A. Young report on Form 4?
He received 9,000 stock options on 06/25/2025 at an exercise price of $1.56 per share.

When do the newly granted CAMP options vest?
They vest fully on the earlier of one year from grant or the company’s next annual meeting, subject to board service.

What is the expiration date of the CAMP options granted to Richard A. Young?
The options expire on 06/24/2035.

Did the Form 4 disclose any open-market purchases or sales of CAMP common stock?
No. The filing only reports an option grant; no common share transactions were listed.

How many CAMP derivative securities does Richard A. Young own after the transaction?
He beneficially owns 9,000 derivative securities (stock options) following the grant.

Was the option grant to Richard A. Young made under a Rule 10b5-1 trading plan?
The form includes a checkbox for Rule 10b5-1 but does not indicate that the transaction was pursuant to such a plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Young Richard A
(Last) (First) (Middle)
C/O CAMP4 THERAPEUTICS CORPORATION
ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.56 06/25/2025 A 9,000 (1) 06/24/2035 Common Stock 9,000 $0 9,000 D
Explanation of Responses:
1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.
Remarks:
/s/ Josh Mandel-Brehm, as Attorney-in-Fact 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR